Home  »  Business   »  Viking Therapeutics Inc. (VKTX) Stock: Analyzing t...

Viking Therapeutics Inc. (VKTX) Stock: Analyzing the Market Value

, and the 36-month beta value for VKTX is at 0.70.

The average price suggested by analysts for VKTX is $19.22, which is $8.32 above the current market price. The public float for VKTX is 67.77M, and currently, shorts hold a 7.15% of that float. The average trading volume for VKTX on March 15, 2023 was 4.13M shares.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


VKTX) stock’s latest price update

Viking Therapeutics Inc. (NASDAQ: VKTX)’s stock price has increased by 3.51 compared to its previous closing price of 10.53. Despite this, the company has seen a loss of -3.80% in its stock price over the last five trading days. The Wall Street Journal reported on 06/17/21 that CureVac, Honest, Bank Stocks: What to Watch When the Stock Market Opens Today

VKTX’s Market Performance

VKTX’s stock has fallen by -3.80% in the past week, with a monthly rise of 2.16% and a quarterly rise of 196.20%. The volatility ratio for the week is 6.62% while the volatility levels for the last 30 days are 5.19% for Viking Therapeutics Inc. The simple moving average for the last 20 days is -2.09% for VKTX stock, with a simple moving average of 112.92% for the last 200 days.

Analysts’ Opinion of VKTX

Many brokerage firms have already submitted their reports for VKTX stocks, with BTIG Research repeating the rating for VKTX by listing it as a “Buy.” The predicted price for VKTX in the upcoming period, according to BTIG Research is $20 based on the research report published on July 29th of the previous year 2021.

Raymond James, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $12, previously predicting the price at $27. The rating they have provided for VKTX stocks is “Outperform” according to the report published on May 25th, 2021.

BMO Capital Markets gave a rating of “Outperform” to VKTX, setting the target price at $14 in the report published on June 05th of the previous year.

VKTX Trading at 10.85% from the 50-Day Moving Average

After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.05% of loss for the given period.

Volatility was left at 5.19%, however, over the last 30 days, the volatility rate increased by 6.62%, as shares surge +2.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.95% upper at present.

During the last 5 trading sessions, VKTX fell by -3.80%, which changed the moving average for the period of 200-days by +388.79% in comparison to the 20-day moving average, which settled at $11.15. In addition, Viking Therapeutics Inc. saw 15.96% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at VKTX starting from FOEHR MATTHEW W, who purchase 45,000 shares at the price of $2.47 back on May 02. After this action, FOEHR MATTHEW W now owns 111,250 shares of Viking Therapeutics Inc., valued at $111,195 using the latest closing price.

Stock Fundamentals for VKTX

Equity return is now at value -42.80, with -38.70 for asset returns.


In conclusion, Viking Therapeutics Inc. (VKTX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.